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Abstract
Aims and Objectives: This study aims to analyze immunocytochemically p53 aberrant expression and mdm-2
expression in primary and recurrent mucoepidermoid carcinoma (MEC) of parotid gland and to ascertain if
expression of these markers correlates with tumor behavior, clinical outcome, histological grade and local
recurrence.
Methods: 20 cases histologically diagnosed as primary MEC with different grades were included in the study. Out
of 20 cases, 7 were classified as grade I, 8 as grade II and 5 as grade III. Immunohistochemical staining of these 20
primary cases as well as 6 recurrent cases with anti-p53 and anti-mdm-2 antibodies was carried out. Area fraction
of immunopositivity was estimated by image analysis software.
Results: 16/20 primary cases were p53 +ve (80%). The p53 positive cases included 3 cases classified as grade (I), 8
cases as grade (II) and 5 cases as grade (III). All 6 recurrent cases were p53 +ve. On the other hand, 14/20 primary
and only 2/6 recurrent cases were mdm-2 +ve. The mdm-2 +ve primary cases included 2 classified as grade (I), 7
as grade (II) and 5 as grade (III). 12 primary MEC showed co-expression of both p53 and mdm-2 of which 2 cases
showed local recurrence.
Conclusions: these data suggested that expression of p53 and mdm-2 in primary and recurrent MEC correlates
with the high histological grade. P53 aberrant expression is not only considered as an early event in MEC
carcinogenesis but also correlates to tumor behavior and local recurrence. Mdm-2 overexpression is correlated to
pathogenesis of MEC. However, no strong evidence was found between mdm-2 expression and MEC local
recurrence.
Background
Malignant tumors of the major salivary glands are rare,
representing 7% of all head and neck cancers. Benign
and malignant parotid gland neoplasms account for
approximately 90% of all major salivary tumors. They
are characterized by a variety of histologic subtypes with
different biologic and prognostic behavior [1].
Recent studies of the molecular biology of cancers
have demonstrated that the loss of function of tumor
suppressor genes may elicit tumorigenesis, and may be
associated with the development and progression of
many different cancer types. One of the best known
tumor suppressor genes is the p53 gene [2]. This gene is
located on human chromosome 17(p13) and encodes a
nuclear phosphoprotein (53 Kd) that thought to regulate
proliferation of normal cells [2]. Various point muta-
tions of the p53 gene usually determine the transcrip-
tion of a mutated protein, which is much more
metabolically stable than the wild protein and accumu-
lates in the nucleus. Consequently, normal cells with the
wild p53 gene do not show p53 immunoreactivity,
whereas tumors with the mutant form of the p53 gene
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histochemically detectable. The accumulation of the p53
oncoprotein clearly has been shown to correlate with
shorter survival in patients with carcinomas of the
breast, lung, stomach, colon as well as bladder [3].
The mdm-2 oncogene was first cloned as an amplified
gene on a murine double-minute chromosome in the
3T3DM cell line, a spontaneously transformed derivative of
BALByc 3T3 cells [4]. The gene encodes a 489 amino acid
polypeptide that contains a p53 binding domain, an acidic
region, and three putative zinc-binding motifs (one zinc-
finger and one RING finger). Overexpression of the mdm-2
gene in NIH 3T3 cells increases the tumorigenic potential
of these cells, thus establishing mdm-2 as an oncogene [4].
The mdm-2 gene can immortalize rat embryo fibroblasts
and cooperate with the activated ras oncogene to transform
these cells [5]. The mdm-2 gene is amplified or overex-
pressed in about 40-60% of human osteogenic sarcomas
and about 30% of soft tissue sarcomas [4,5], implicating its
role in the development of these malignancies.
An important function of mdm-2 is to bind to the p53
tumor suppressor protein, inhibiting its ability to act as a
transcription factor [6]. P53 also activates mdm-2 expres-
sion at the level of transcription suggesting that mdm-2
can function as a negative feedback regulator of p53 [7].
Several studies were carried out to investigate the role
of aberrant expression of p53 tumor suppressor gene
and mdm-2 overexpression in different benign and
malignant salivary gland tumors [8,9]. However, no defi-
nite data was available in the literature regarding the
exact role of p53 and mdm-2 mutation upon the clinical
coutcome of muco-epidermoid carcinoma as one of the
common malignant salivary gland tumors and also the
factors that might be related to the aggressiveness and
recurrence of these tumors.
The aim of this study is to analyze immunocytochemi-
cally p53 aberrant expression and mdm-2 expression in
primary and recurrent MEC of parotid gland and to
ascertain if expression of these markers correlates with




Twenty cases of primary muco-epidermoid carcinoma of
the parotid gland collected from June 1998 through
December 2004 were obtained from the files of the
Pathology Department, National Cancer Institute, Cairo
University (Cairo, Egypt). Clinical information was
obtained from the patients’ clinical records. Clinical sta-
ging was assayed by using the International Union
Against Cancer (1987) TNM staging system [10].
All of the patients with parotid masses were surgically trea-
ted with total parotidectomy. Facial nerve preservation was
performed in 14 (70%) of the cases. A facial nerve weakness
by tumor infiltration in 12 (60%) and a close tumor adher-
ence to the main trunk or to one of the main division
branches of the facial nerve justified its partial or total sacri-
fice in 6 (30%) of the cases. Total parotidectomy was per-
formed in association with homolateral radical neck
dissection in six (N1) cases and with functional neck dissec-
tion in five (N0) cases. In addition, 2 patients who did not
undergo neck procedures associated with the parotid surgery
presented with regional lymph node metastases and under-
went radical neck dissection during the follow-up period.
Pathologic examination of the neck specimens con-
firmed tumor involvement in all patients with clinically
palpable cervical lymph nodes.
After primary surgery, 11 of 20 cases (55%), including
all patients with cervical lymph node metastases and
those with clinical signs of local infiltration of skin,
bone, muscle, and facial nerve, received a full course of
postoperative radiotherapy to the parotid area and to
the neck.
All patients were followed for a minimum of 36
months (mean follow-up, 42 months).
Tissue samples and immunohistochemistry
Formalin fixed, paraffin embedded specimens of the
primary parotid gland tumors from each patient were
available for immunohistochemical analysis. Tissue spe-
cimens from recurrent cases were also included in the
analysis. Immunohistochemistry was performed on
deparaffinized, 5-μm sections after antigen retrieval
using microwave oven heating.
A murine monoclonal antibody, DO-7 antihuman p53
protein, specific for a formalin-resistant epitope of the
N-terminus of the human protein reacting with both
wild and mutant types of the p53 protein (Dako, Copen-
hagen, Denmark) was used.
For immunodetection of mdm-2, anti-mdm-2 mouse
IgG-Kappa monoclonal antibody specific for epitope
located within the amino acids 26-169 of the human
mdm-2 protein (Zymed Laboratories Inc., USA) was used.
For immunostaining, the avidin-biotin-peroxidase com-
plex method was used according to manufacturer
instructions. In brief, after deparaffinization and inactiva-
tion of endogenous peroxidase activity and blocking of
cross reactivity with pre-immune serum (Peroxide Block
Kit, Zymed Laboratories Inc., USA), the sections were
incubated for 1 hour at room temperature with the pri-
mary antibody diluted at 1:50. Localization of the primary
antibody was achieved by subsequent incubation of bioti-
nylated anti-primary antibody with an avidin- biotin
complex conjugated to horseradish peroxidase, and dia-
minobenzidine (Zymed Laboratories Inc., USA). The
slides were washed three times with phosphate buffered
saline after each incubation. Negative controls were
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Image Cytometric Analysis
In this study, the immunostaining of each antibody was
assessed in 4 serial sections from each specimen. For eva-
luation of p53 and mdm-2 immunoreactivity, tumor cells
were considered immunopositive when they displayed a
brownish nuclear and/or cytoplasmic immunoreactivity.
Surface area of the immunopositivity was calculated by
using the image analysis software (ImageJ, NIH, 1.31b,
USA) and the area fraction of immunopositivity was then
estimated by calculating the ratio of surface area of
immunopositive cells to the total area of the microscopic
field. Data were then collected, tabulated for further sta-
tistical assessment of the results.
Statistical Analysis
ANOVA test followed by Post Hoc multiple compari-
s o nt e s t( T u k e yH S Dm e t h o d )w e r ep e r f o r m e dt o
compare the mean area fraction of immunopositivity
(Nuclear and/or cytoplasmic) of either p53 or mdm-2
in primary and recurrent cases in relation to different
grades of MEC. Welch two sample t-test was per-
formed to compare mean area fraction of immunoposi-
tivity in primary versus recurrent cases for each
antibody separately. Pearson’s correlation was done
to study the correlation between P53 and mdm-2
immunopositivity in different grades of primary and
recurrent MEC.
Statistical analysis for survival rates was not performed
a st h ed a t af o rt i m eo fm o r t a l i t ya f t e rt h ep r i m a r ys u r -
gery was not available.
Results and Discussion
After follow-up period of all patients, 6 cases showed
evidence of recurrence (30% of cases). The time elapsed
between the surgical removal of the primary lesion and
the recurrence was variable and ranged from 32-40
months.
Figure 1 Low grade MEC showing cystic spaces and duct-like structures lined by mucous-secreting cells together with few
differentiated epidermoid cells (HE × 200).
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Out of the twenty cases under study, 7 (35%) were his-
tologically graded as low grade (Grade I) (Figure 1), 8
(40%) were histologically graded as intermediate grade
(Grade II) (Figure 2) and 5 (25%) were graded as high
grade (Grade III) (Figure 3).Three recurrent lesions were
histologically graded as high grade (grade III) while the
remaining three lesions were graded as intermediate
grade (grade II). Two other patients rather than the six
recurrent cases died after surgical removal of the pri-
mary tumor due to distant metastasis to the bones.
(Table 1) demonstrated the clinical data of all cases
under study and the histopathological grading of lesions.
P53 Immunohistochemical Results
Sixteen out of the 20 primary cases under study showed
positive immunostaining for p53 (80%). The p53 positive
cases included 3 classified as grade (I), 8 as grade (II)
and 5 as grade (III) (Table 2). The reaction was nuclear
or nuclear/cytoplasmic in localization and granular
brownish in nature. The immunopositivity was confined
to epidermoid cells that formed cell nests while the
vacuolated mucous secreting cells that formed duct-like
structures were immunonegative (Figure 4). The positive
nests of epidermoid cells showed nuclear staining of
most of the peripheral cells with few immunopositivity
noted in the central cells.
The six recurrent cases showed p53 immunopositivity
(Table 2). The localization and nature of the reaction
was similar to the primary lesions. However, the immu-
nopositivity was confined to the epidermoid cells that
formed the advancing front of the nests (Figure 5).
Mdm2 Immunohistolochemical Results
Fourteen out of the 20 primary lesions (70%) were positively
stained with mdm2. The mdm-2-positive cases included 2
lesions classified as grade (I), 7 cases as grade (II) and 5
cases as grade (III) (Table 2). The reaction was brownish
and granular in nature and was cytoplasmic in most of posi-
tive cells with few cells showed nuclear/cytoplasmic localiza-
tion of the immunoreaction. The majority of the neoplastic
epidermoid cells were immunopositive while the mucous
Figure 2 Intermediate grade MEC showing tumor nests formed of epidermoid cells intermingled with clear mucous cells together
with duct-like structures lined by both types of cells (HE × 200).
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keratinization. Note the few scattered mucous-secreting cells (HE × 200).
Table 1 Clinicopathologic data of all cases under study
Case Age Gender Histological grade Facial nerve involvement Metastasis Recurrence
13 5 ♂ II 1* N0 0**
22 2 ♀ III 1 N1 0
31 5 ♂ II 1 N1 1
44 9 ♀ II 1 N0 0
54 4 ♀ I 0 N0 0
63 3 ♀ III 1 N1 1
71 7 ♂ II 1 N1 1
81 1 ♂ III 1 N1 1
92 4 ♀ I 0 N0 0
10 60 ♂ II 1 N0 0
11 38 ♀ I 0 N0 0
12 46 ♀ II 1 N1 1
13 16 ♂ II 1 N0 0
14 48 ♂ I 0 N0 0
15 51 ♂ III 1 N1 1
16 46 ♀ III 1 N1 0
17 13 ♀ II 0 N0 0
18 57 ♂ I 0 N0 0
19 14 ♀ I 0 N0 0
20 31 ♂ I 0 N0 0
*1=Y e s* *0=N o
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well as central cells of the tumor nests showed immuno-
positive reaction (Figure 6).
Two lesions only out of the six recurrent cases
showed immunopositivity to mdm2 (Table 2). The
immunopositivity was noted in epidermoid cells that
surrounded the central keratinized cells while most of
the peripheral tumor cells as well as mucous secreting
cells that formed the duct-like structure were immuno-
negative (Figure 7).
Image Cytometric Results
The mean area fraction of p53 immunopositivity in pri-
mary MEC was (23.1%) while the mean area fraction of
recurrent cases was (18.2%). On the other hand, the mean
area fraction of mdm-2 immunopositivity was (40.9%) and
(34.1%) in primary and recurrent MEC respectively.
A summary of the mean area fraction of immunoposi-
tivity in both primary and recurrent MEC stained with
p53 and mdm-2 is shown in (table 3).
Statistical Results
ANOVA test and Post Hoc multiple comparisons test
revealed a statistically significant increase in the mean
area fraction of p53 or mdm-2 immunopositivity from
low grade to high grade MEC (Tables 4, 5).
Welch two samples t-test showed a statistically signifi-
cant decrease in the expression of either p53 or mdm-2
Table 2 Summary of P53 and Mdm-2 immunopositive






Primary Recurrent Primary Recurrent
N0 N1 N0 N1 N0 N1 N0 N1
Grade I 3 0 0 0 2 0 0 0
Grade II 5 3 0 3 4 3 0 1
Grade III 2 3 0 3 2 3 0 1
Total 10 6 0 6 8 6 0 2
Grand Total 16 6 14 2
Figure 4 Primary MEC showing positive nuclear immunostaining of epidermoid cells forming tumor nests. The mucous cells were
immunonegative (Anti-p53 × 100).
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nests. The mucous cells were immunonegative (Anti-p53 × 100).
Figure 6 Primary MEC showing positive nuclear and cytoplasmic immunostaining of epidermoid cells forming tumor nests.T h e
mucous cells were immunonegative (Anti-mdm-2 × 100).
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grade (Table 6).
On the other hand, regression analysis revealed a linear
positive correlation between the expression of p53 and
mdm-2 in relation to either tumor grade in both primary
and recurrent MEC (Figure 8). However, this correlation
was not proved to be existed when comparing the expres-
sion of both markers in recurrent cases only (Table 7).
Discussion
This aim of the present study was to investigate the
immunoexpression of p53 and mdm2 oncoproteins in
primary and recurrent MEC as a trial to clarify the pos-
s i b l er o l eo ft h o s ep r o t e i n si nt h ep a t h o g e n e s i so ft h i s
tumor and also to correlate the effect of their expression
on the recurrence and clinical outcome of these tumors
of salivary glands.
Earlier studies focused on the analysis of p53 gene in
tumors of the salivary glands; however the connection
between salivary gland carcinogenesis and the mdm2
oncoprotein was still elusive [11]. Some authors demon-
strated that not only p53 gene is a potential target in
neoplastic transformation, but also genes involved in the
regulation of its function since mdm2 can potently regu-
late p53, and functions as an oncogene in the process of
cell transformation [12]. For this reason co-expression
of both p53 and mdm2 was investigated for their role in
the biological behavior of MEC.
Interpretation of immunohistochemical positivity as
mild, moderate and intense reaction is now considered
as an obsolete method as it lacks the basic standardized
parameters upon which the results are interpreted and
also due to difficulty to avoid the subjectivity in estimat-
ing the degree of immunostaining. For this reason, a
novel method of image analysis by which the results
were automatically estimated as a surface area of immu-
nopositivity is widely used [13].
Figure 7 Recurrent MEC showing positive nuclear and cytoplasmic immunostaining of epidermoid cells forming tumor nests.T h e
mucous cells were immunonegative (Anti-mdm-2 × 100).
Table 3 Summary of mean area fraction of both p53 and
mdm-2 immunopositivity in relation to recurrence in
different grades of MEC:




Primary Recurrent Primary Recurrent
Grade I 13.2 0 33.4 0
Grade II 25.3 16.5 39.9 31.9
Grade III 30.7 19.8 49.3 36.2
Grand Mean 23.1 18.2 40.9 34.1
Abd-Elhamid and Elmalahy Diagnostic Pathology 2010, 5:72
http://www.diagnosticpathology.org/content/5/1/72
Page 8 of 13Many authors considered both nuclear and cytoplas-
mic staining or exclusively cytoplasmic staining as posi-
tive results [14], and this was chosen for assessment of
immunopositive reaction of mdm2 in this study, because
a strong evidence is now available that mdm2 is an RNA
binding protein that can shuttle between the nucleus
and the cytoplasm, and both mdm2 and p53 proteins
contain a nuclear-import and nuclear-export signals
(NES) that enable them to be directed into the nucleus
and out again towards the cytoplasm [14]. This NES of
mdm2 is essential for p53 degradation by interacting
with cytoplasmic proteasomes, where p53 is specifically
degraded [15].
Immunohistochemical results of the present study
revealed that 80% of primary lesions showed immuno-
positive expression of p53. These results were in accor-
dance with that found by many authors who reported
an immunopositive expression of aberrant p53 in gland-
ular carcinomas including those of salivary glands and
considered expression of mutant p53 as an early event
in malignant transformation of these tissues [9,16-18].
Nordkvist et al [19] and Ohki et al [20] have detected
Table 4 ANOVA test and Post Hoc multiple comparisons of mean area fraction of p53 immunopositivity in relation to
different grades of MEC:
Descriptive statistics (P53)
Grade Number of fields (Records) Mean Area Fraction Standard Deviation
Grade I 12 13.18917 1.426180
Grade II 44 20.91700 5.846319
Grade III 32 25.26250 7.679862
ANOVA (p53)
P53 Sum of Squares df Mean Square F P Value
Between Groups 1295.4 2 647.68 16.478 0.0001
Within Groups 3183.8 81 39.31
Total 686.99 83
Post Hoc (Tukey HSD)
Dependent Variable (I) Groups (J) Groups Mean Diff. P Value Significance
P53 Mean Area Fraction Grade I Grade II -7.727833 < 0.001 S*
Grade III -12.073333 < 0.001 S
Grade II Grade III - 4.345500 < 0.001 S
* The mean difference is significant at the 0.05 level
Table 5 ANOVA test and Post Hoc multiple comparisons of mean area fraction of mdm-2 immunopositivity in relation
to different grades of MEC:
Descriptive statistics (mdm-2)
Grade Number of fields (Records) Mean Area Fraction Standard Deviation
Grade I 8 32.16375 1.264538
Grade II 32 35.95156 7.165884
Grade III 24 42.77000 5.654459
ANOVA (mdm-2)
Sum of Squares df Mean Square F P Value
Mdm-2 Between Groups 952.76 2 476.38 12.427
Within Groups 2338.42 61 38.33 0.0001
Total 3291.18 63
Post Hoc (Tukey HSD)
Dependent Variable (I) Groups (J) Groups. Mean Diff P Value Significance
Mdm-2 Mean Area Fraction Grade I Grade II -3.787812 < 0.001 S*
Grade III -10.606250 < 0.001 S
Grade II Grade III - 6.818438 > 0.05 NS
* The mean difference is significant at the 0.05 level
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small number of MEC cases were analyzed in these stu-
dies, p53 gene alterations were identified, suggesting a
possible involvement of this gene in MEC pathogenesis.
Matizonkas-Antontio et al [1] utilizing single-stranded
conformational polymorphism (SSCP) analysis for p53
mutations in salivary gland tumors confirmed these data
and reported that p53 mutations in exons 5 and 8 were
most likely related to salivary gland neoplasms. They
a d d e dt h a tm u t a t i o n sw e r eo b s e r v e di n1o f3o fM E C
cases under study. On the other hand, Karja et al [18]
did not observe any p53 mutations in these lesions sug-
gesting variable results regarding p53 gene status in
these lesions.
P53 immunopositivity of epidermoid cells observed in
the present study might indicate the proliferative nature
of these cells when compared to a more differentiated
mucous-secreting cells. These results together with that
Table 6 Welch two samples t-test for comparison of mean area fraction (AF) of p53 and mdm-2 immunopositivity in
primary versus recurrent MEC:
Welch Two Sample t-test (P53)
Dependent Variable MEC Mean AF 95% Confidence Interval t df P value
Lower Bound Upper Bound
P53 Mean Area Fraction Primary MEC 23.12033 4.042945 9.200222 5.1179 72.87 0.00001
Recurrent MEC 18.23875
Welch Two Sample t-test (Mdm-2)
Dependent Variable MEC Mean AF 95% Confidence Interval t df P value
Lower Bound Upper Bound
Mdm-2 Mean Area Fraction Primary MEC 40.89893 6.800357 11.822500 7.5658 30.697 0.00001
Recurrent MEC 34.14750
* The mean difference is significant at the 0.05 level
Figure 8 A scatter plot representing a linear positive correlation between p53 and mdm-2 expression in MEC.
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image analysis suggested a more expression of p53 in
these aggressive cell population in MEC indicating a
possible relationship between alteration of p53 function
and malignant transformation of these cells [18]. This
suggestion might explain the immunopositivity of p53 in
all intermediate and high grade cases containing predo-
minantly a more aggressive epidermoid and intermediate
cells while only 3 out of 7 cases classified as grade (I)
showed p53 immunopositivity due to presence of a
more differentiated and less aggressive mucous-secreting
cells in these lesions.
Immunopositivity of p53 in all recurrent cases noted in
the present study strongly suggested the argument of
Oreste Gallo et al [8] who stated that p53 expression
tended to be higher in late stage cancers, correlated with
clinicopathologic variables indicative of aggressiveness,
such as regional and distant metastases; and provided
prognostic information for disease free and overall survi-
val probabilities. In fact, the above-mentioned trends
found in p53-positive parotid gland cancers indicated
that p53 gene expression does influence tumor behavior
and strongly suggested that parotid gland carcinomas
showing high p53 oncoprotein immunoreactivity are
aggressive and have a poor prognosis as already was
observed for other glandular carcinomas such as lung,
breast, stomach, and colon cancer [3].
Mdm-2 immunohistochemical results of the present
study revealed that 70% of MEC showed mdm-2 immu-
nopositivity. These data agreed with those reported by
Haitel et al [21] and Higashiyama et al [22] who
reported an overexpression of mdm-2 oncoprotein in
clear cell renal carcinoma and non-small cell lung can-
cer respectively.
However, de Araujo et al [9] found that the expression
of mdm-2 in malignant tumors of minor salivary glands
is not significantly high when compared to that in
benign tumors.
On the other hand, only 2 out of the six recurrent
cases showed mdm-2 immunopositivity. These data sug-
gested that expression of mdm-2 is an early event in the
carcinogenic pathway of MEC and hence the lowered
percentage of mdm-2 immunopositivity is usually
related to tumors of better prognosis and/or low recur-
rence rate [23].
The data of the present study also revealed that out of
the 16 p53 immunopositive primary cases, 12 were
mdm-2- positive while only 4 cases were p53 +ve/mdm-
2 -ve. The high percentage of primary MEC that showed
co-expression of both p53 and mdm-2 together with the
linear correlation noted by regression analysis might
indicate the possible interaction between these two pro-
t e i n s .O n ep o s s i b l es c e n a r i o of this interaction is that
p53 aberrant expression as an early event in the carcino-
genic cascade of MEC led to activation of mdm-2 feed-
back loop for proteasome degradation of activated p53
[14]. Despite the activation of mdm-2, degradation of
p53 do not takes place. One explanation of this argu-
ment is that mdm-2 had two apparently opposite func-
tions, a tumorigenic function and a growth arrest one.
Table 7 Correlation with regression analysis of p53 and mdm-2 immunopositivity in primary and/or recurrent MEC
Pearson’s Correlation (in both primary and recurrent cases)
Mean AF-p53 Mean AF-Mdm-2
Mean AF-p53 Pearson Correlation 1 0.4762 (**)
Sig. (2-tailed) 0.0001
Mean AF-Mdm-2 R Squared 0.4762 (**) 1
Sig. (2-tailed) 0.0001
Pearson’s Correlation (in primary cases only)
Mean AF-p53 Mean AF-Mdm-2
Mean AF-p53 Pearson Correlation 1 0.3864 (**)
Sig. (2-tailed) 0.0001
Mean AF-Mdm-2 R Squared 0.3864 (**) 1
Sig. (2-tailed) 0.0001
Pearson’s Correlation (in recurrent cases only)
Mean AF-p53 Mean AF-Mdm-2
Mean AF-p53 Pearson Correlation 1 -0.08434
Sig. (2-tailed) 0.5249
Mean AF-Mdm-2 R Squared -0.08434 1
Sig. (2-tailed) 0.5249
** Correlation is significant at the 0.01 level (2-tailed).
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mdm-2 expressed in the cell and also the balance of
positive and negative regulators of cell cycle which is
critical for the control of cell proliferation [24].
Another explanation is that phosphorylation of the amino
terminus of p53 does not affect its DNA binding ability, but
does affect its affinity for mdm-2 and subsequent p53 degra-
dation [25]. So, overexpression of p53 would increase the
levels of mdm-2 by the feed back loop but without affecting
the activity of phosphorylated p53 [25].
These explanations on the immunohistochemical level
would focus on the role of these two proteins in the
pathogenesis and clinical outcome of MEC, however,
further studies utilizing much more advanced research
tools such as in situ hybridization and SSCP analysis are
highly recommended.
Conclusions
Based upon the results of the present study, it could be
concluded that:
￿ Expression of p53 and mdm-2 in primary and
recurrent MEC correlates with the high histological
grade.
￿ P53 aberrant expression is not only considered as
an early event in MEC carcinogenesis but also corre-
lates to tumor behavior and local recurrence.
￿ Mdm-2 overexpression is correlated to pathogen-
esis of MEC. However, no strong evidence was
found between mdm-2 expression and MEC local
recurrence.
Author details
1Associate Professor, Oral Pathology Department, Faculty of Dentistry, Ain
Shams University, Cairo, Egypt.
2Associate Professor, Oral Pathology
Department, Faculty of Oral and Dental Medicine, Elmenia University, Cairo,
Egypt.
Authors’ contributions
E.S.A Participated in the study design, collection of the background
references, photomicrography of the immunohistochemical results,
interpreting and displaying the results of the study, writing the discussion of
the results, alignment of the references, carried out the sequence alignment
and drafted the manuscript.
M.H.E participated in the study design, collection of the background
references, carried out the immunohistochemical technique, participated in
displaying the results of the study, writing the discussion of the results and
alignment of the references.
Competing interests
The authors declare that they have no competing interests.
Received: 18 August 2010 Accepted: 22 November 2010
Published: 22 November 2010
References
1. Matizonkas-Antonio LF, Mesquita RA, Machado de Souza SO, Nunes FD:
TP53 mutations in salivary gland neoplasms. Braz Dent J 2005,
16(2):162-166.
2. Argawal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR: The P53
network. J Biol Chem 1998, 273:1-4.
3. Harris CC, Hollstein M: Clinical implications of the p53 tumor suppressor
gene. N Engl J Med 1993, 329:1318-27.
4. Chen L, Agarwal S, Zhou W, Zhang R, Chen J: Synergistic activation of p53
by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci
1998, 95:195-200.
5. Zhang Z, Li M, Wang H, Agarwal S, Zhang R: Antisense therapy targeting
MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis,
multiple gene expression, and chemotherapy. PNAS 2003,
100(20):11636-11641.
6. Ranju R, Agarwal M, Mathur M, Wasylyk B, Shukla K: Induction of mdm2-p2
transcripts correlates with stabilized wild-type p53 in betel- and
tobacco-related human oral cancer. Am J Pathol 2000, 157:587-596.
7. Prives C, Hall P: The p53 pathway. J Pathol 1999, 187:112-126.
8. Gallo O, Franchi A, Bianchi S, Boddi V, Giannelli E, Alujmo E: p53
oncoprotein expression in parotid gland carcinoma is associated with
clinical outcome. Cancer 1995, 75(8):2037-2044.
9. de Araujo V, Martins M, Leite R, Gomez N: Immunohistochemical mdm-2
expression in minor salivary gland tumors and its relationship to p53
gene status. Oral Oncol 2000, 36:67-69.
10. Sobin LH, Wittekind CH, International Union Against Cancer (UICC): TNM
Classification of Malignant Tumours. New York: Wiley;, 5 1997.
11. Giordana M, Duo D, Gasverde S, Trevisan E, Boghi A, Morra I, Pradotto L,
Mauro A: Mdm-2 overexpression is associated with short survival in
adults with medulloblastoma. Neuro-oncol 2002, 4:115-122.
12. Chen J, Marechal V, Levine A: Mapping of the p53 and mdm-2 interaction
domains. Mol Cell Biol 1993, 13:4107-4114.
13. Sompuram R, Kodela V, Zhang K, Ramanathan H, Radcliffe G, Falb P,
Bogen A: A novel quality control slide for quantitative
immunohistochemistry testing. J Histoch & Cytoch 2002, 50:1425-1434.
14. O’Keefe K, Li H, Zhang Y: Nucleocytoplasmic shuttling of p53 is essential
for mdm-2-mediated cytoplasmic degradation but not uubiquitination.
Mol Cell Biol 2003, 23:6396-6405.
15. Claudio P, Zamparelli A, Garcia F, Claudio L, Ammirati G, Farina A,
Bovicelli A, Russo G, Giordano G, McGinnis D, Giordano A, Cardi G:
Expression of cell cycle regulated proteins pRb2/p130, p107, p27Kip-1,
p53, mdm-2 and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin
Cancer Res 2002, 8:1808-1815.
16. Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R, Hugh-
Jones T: Mdm-2 and the p53 pathway in human pituitary adenomas. Clin
Endocrinol 2001, 23:317-325.
17. Sheikh M, Shao Z, Hussain A, Fontana J: The p53 binding protein mdm2
gene is differentially expressed in human breast carcinoma. Cancer Res
1993, 53:3226-3228.
18. Karja VJ, Syrjanen KJ, Kurvinen AK, Syrjanen SM: Expression and mutation
of P53 in salivary gland tumours. J Oral Pathol Med 1997, 26:217-223.
19. Nordkvist A, Roijer E, Bang G, Gustafsson H, Behrendt M, Ryd W,
Thoresen S, Donath K, Stenman G: Expression and mutation patterns of
P53 in benign and malignant salivary gland tumors. Int J Oncol 2000,
16:477-483.
20. Ohki K, Kumamoto H, Ichinohasama R, Suzuki M, Yamaguchi T, Echigo S,
Motegi K, Ooya K: Genetic analysis of DNA microsatellite loci in salivary
gland tumours: comparison with immunohistochemical detection of
Hmsh2 and P53 proteins. Int J Oral Maxillofac Surg 2001, 30:538-544.
21. Haitel A, Weiner H, Beathge U, Marberger M, Susani M: Mdm2 expression
as a prognostic indicator in clear cell renal cell carcinoma: Comparison
with p53 overexpression and clinicopathological parameters. Clin Cancer
Res 2000, 6:1840-1844.
22. Higashiyama M, Doi O, Kodoma K, Kasugai T, Ishiguro S, Takami K,
Nakayama T, Nishisho I: Mdm2 gene amplification and expression in non-
small-cell lung cancer: Immunhistochemical expression of its protein is a
Abd-Elhamid and Elmalahy Diagnostic Pathology 2010, 5:72
http://www.diagnosticpathology.org/content/5/1/72
Page 12 of 13favorable prognostic marker in patients without p53 protein
accumulation. Br J Cancer 1997, 75:1302-1308.
23. Roijer E, Nordkvist A, Storm A, Ryd W, Behrendt M, Bullerdiek J, Mark J,
Stenman G: Translocation, deletion/amplification and expression of
HMGIC and mdm2 in a carcinoma ex pleomorphic adenoma. Am J
Pathol 2002, 160:433-440.
24. Brown D, Thomas C, Deb S: The human oncoprotein mdm2 arrests the
cell cycle: elimination of its cell-cycle inhibitory function induces
tumorigenesis. EMBO J 1998, 17:2513-2525.
25. Vogelstein B, Lane D, Levine A: Surfing the p53 network. Nature 2000,
408:307-310.
doi:10.1186/1746-1596-5-72
Cite this article as: Abd-Elhamid and Elmalahy: Image cytometric
analysis of p53 and mdm-2 expression in primary and recurrent
mucoepidermoid carcinoma of parotid gland: immunohistochemical
study. Diagnostic Pathology 2010 5:72.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Abd-Elhamid and Elmalahy Diagnostic Pathology 2010, 5:72
http://www.diagnosticpathology.org/content/5/1/72
Page 13 of 13